Deep Track Capital’s Adicet Bio ACET Stock Holding History

Deep Track Capital’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-51,594	Closed	-$11.7M	–	61
2022 Q3	$11.7M	Sell	51,594 -4,158	-7%	-$1.06M	0.54%	49
2022 Q2	$13M	Buy	+55,752	New	+$12.2M	0.86%	35

Other funds holding ACET

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Deep Track Capital's ACET Position: Q4 2022 in Review

Deep Track Capital sold out of Adicet Bio (ACET) in Q4 2022, closing a stake of 51,594 shares — an estimated $11.7M sold.

Deep Track Capital first reported a position in ACET in Q2 2022 and held it in 2 quarters. The position peaked at $13M in Q2 2022. 99 funds tracked by Wall St. Rank hold ACET as of Q4 2022.

Deep Track Capital reported no remaining Adicet Bio position as of Q4 2022 after selling out during the quarter.
Deep Track Capital sold 51,594 Adicet Bio shares in Q4 2022, an estimated $11.7M.
Deep Track Capital first reported a position in Adicet Bio in Q2 2022 and held it in 2 quarters.
Deep Track Capital's Adicet Bio position peaked at $13M in Q2 2022.
99 funds tracked by Wall St. Rank held Adicet Bio as of Q4 2022.

Based on Deep Track Capital's 13F filing for Q4 2022, filed 14 Feb 2023.